Clinical trial results
for previously
treated advanced
kidney cancer
For certain adults with previously treated advanced
kidney cancer (renal cell carinoma)
Clinical trial results
for previously
treated advanced
kidney cancer
For certain adults with previously treated advanced
kidney cancer (renal cell carinoma)
Actor portrayals.
OPDIVO is not approved for people
younger than 18 years of age.
In a clinical trial of 821 people with previously treated advanced kidney cancer, 410 people were given OPDIVO and 411 people were given everolimus, a standard treatment.
Half the people were alive
Half the people were alive
In a clinical trial, people given OPDIVO had a 27% lower risk of dying than those given everolimus.
In a clinical trial, tumors shrinking or disappearing completely because of treatment is known as the overall response rate.
Words to know
Overall response rate is the percentage of patients who responded to treatment. These patients saw their tumors either shrink or disappear completely.
OPDIVO will not work for everyone. Individual results may vary.
See your recommended treatment plan and what to expect from an infusion
For adults with previously treated advanced kidney cancer (renal cell carcinoma)
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with kidney cancer (renal cell carcinoma) when your cancer has spread or grown after treatment with other cancer medications.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.